Federal authorities have charged Fat Brands and its chair Andy Wiederhorn for allegedly orchestrating a loan scheme, resulting in wire fraud and tax evasion charges.
Progyny reported first-quarter sales of $278.1 million, slightly below expectations due to increased clients and covered lives. KeyBanc Capital Markets downgraded Progyny from Overweight to Sector Weight, citing concerns about revenue visibility and customer behavior.
Dutch Bros surges as TD Cowen analyst upgrades stock to Buy, citing impressive earnings beat and sales growth. Analyst projects strong performance in 2024 with beverage innovation and loyalty program driving results.
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns reported.